CRMD
Price
$11.49
Change
-$0.01 (-0.09%)
Updated
Jul 25 closing price
Capitalization
855.19M
12 days until earnings call
MBXBF
Price
$0.21
Change
-$0.01 (-4.55%)
Updated
Jul 24 closing price
Capitalization
30.07M
Interact to see
Advertisement

CRMD vs MBXBF

Header iconCRMD vs MBXBF Comparison
Open Charts CRMD vs MBXBFBanner chart's image
CorMedix
Price$11.49
Change-$0.01 (-0.09%)
Volume$1.81M
Capitalization855.19M
Microbix Biosystems
Price$0.21
Change-$0.01 (-4.55%)
Volume$100K
Capitalization30.07M
CRMD vs MBXBF Comparison Chart in %
Loading...
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MBXBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRMD vs. MBXBF commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRMD is a Hold and MBXBF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (CRMD: $11.49 vs. MBXBF: $0.21)
Brand notoriety: CRMD and MBXBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRMD: 93% vs. MBXBF: 438%
Market capitalization -- CRMD: $855.19M vs. MBXBF: $30.07M
CRMD [@Biotechnology] is valued at $855.19M. MBXBF’s [@Biotechnology] market capitalization is $30.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRMD’s FA Score shows that 0 FA rating(s) are green whileMBXBF’s FA Score has 1 green FA rating(s).

  • CRMD’s FA Score: 0 green, 5 red.
  • MBXBF’s FA Score: 1 green, 4 red.
According to our system of comparison, CRMD is a better buy in the long-term than MBXBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRMD’s TA Score shows that 5 TA indicator(s) are bullish while MBXBF’s TA Score has 3 bullish TA indicator(s).

  • CRMD’s TA Score: 5 bullish, 5 bearish.
  • MBXBF’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CRMD is a better buy in the short-term than MBXBF.

Price Growth

CRMD (@Biotechnology) experienced а +5.80% price change this week, while MBXBF (@Biotechnology) price change was -2.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

CRMD is expected to report earnings on Nov 06, 2025.

MBXBF is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRMD($855M) has a higher market cap than MBXBF($30.1M). CRMD has higher P/E ratio than MBXBF: CRMD (45.96) vs MBXBF (26.44). CRMD YTD gains are higher at: 41.852 vs. MBXBF (-26.021). CRMD has higher annual earnings (EBITDA): 17.7M vs. MBXBF (4.35M). CRMD has more cash in the bank: 77.5M vs. MBXBF (14.5M). CRMD has less debt than MBXBF: CRMD (477K) vs MBXBF (5.35M). CRMD has higher revenues than MBXBF: CRMD (82.6M) vs MBXBF (22.7M).
CRMDMBXBFCRMD / MBXBF
Capitalization855M30.1M2,841%
EBITDA17.7M4.35M407%
Gain YTD41.852-26.021-161%
P/E Ratio45.9626.44174%
Revenue82.6M22.7M364%
Total Cash77.5M14.5M534%
Total Debt477K5.35M9%
FUNDAMENTALS RATINGS
CRMD vs MBXBF: Fundamental Ratings
CRMD
MBXBF
OUTLOOK RATING
1..100
5324
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
71100
SMR RATING
1..100
4582
PRICE GROWTH RATING
1..100
4784
P/E GROWTH RATING
1..100
568
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRMD's Valuation (76) in the Medical Specialties industry is in the same range as MBXBF (77) in the null industry. This means that CRMD’s stock grew similarly to MBXBF’s over the last 12 months.

CRMD's Profit vs Risk Rating (71) in the Medical Specialties industry is in the same range as MBXBF (100) in the null industry. This means that CRMD’s stock grew similarly to MBXBF’s over the last 12 months.

CRMD's SMR Rating (45) in the Medical Specialties industry is somewhat better than the same rating for MBXBF (82) in the null industry. This means that CRMD’s stock grew somewhat faster than MBXBF’s over the last 12 months.

CRMD's Price Growth Rating (47) in the Medical Specialties industry is somewhat better than the same rating for MBXBF (84) in the null industry. This means that CRMD’s stock grew somewhat faster than MBXBF’s over the last 12 months.

MBXBF's P/E Growth Rating (8) in the null industry is somewhat better than the same rating for CRMD (56) in the Medical Specialties industry. This means that MBXBF’s stock grew somewhat faster than CRMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRMDMBXBF
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 10 days ago
65%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 12 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MBXBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYLSX92.51N/A
N/A
Rydex Leisure A
DBIVX10.80N/A
N/A
DWS Global Macro S
SEVIX14.85N/A
N/A
SEI US Managed Volatility I (SIMT)
IUESX29.03N/A
N/A
JPMorgan International Focus I
DEMRX26.34N/A
N/A
Macquarie Emerging Markets R

CRMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRMD has been loosely correlated with MURA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CRMD jumps, then MURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRMD
1D Price
Change %
CRMD100%
-0.09%
MURA - CRMD
37%
Loosely correlated
-1.50%
ARTL - CRMD
33%
Poorly correlated
-0.22%
RLYB - CRMD
32%
Poorly correlated
-4.83%
XLO - CRMD
31%
Poorly correlated
+0.96%
AXON - CRMD
30%
Poorly correlated
+3.63%
More

MBXBF and

Correlation & Price change

A.I.dvisor tells us that MBXBF and CRMD have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MBXBF and CRMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBXBF
1D Price
Change %
MBXBF100%
N/A
CRMD - MBXBF
27%
Poorly correlated
-0.09%
TECX - MBXBF
23%
Poorly correlated
+0.18%
BVNKF - MBXBF
21%
Poorly correlated
-2.18%
NBY - MBXBF
20%
Poorly correlated
+3.23%
MMIRF - MBXBF
15%
Poorly correlated
N/A
More